Covington Represents AbbVie in $1.4B Acquisition of Aliada Therapeutics

WASHINGTON—Covington advised AbbVie in its definitive agreement to acquire Aliada Therapeutics, a biotechnology company advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. Under the terms of the agreement, AbbVie will acquire all outstanding Aliada equity for $1.4 billion in cash.

Aliada's lead investigational asset utilizing this delivery technology, ALIA-1758, is an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody in development for the treatment of Alzheimer's disease.

The Covington team was led by Catherine Dargan and Kyle Rabe.